

21861  
030904  
U.S. PTOPTO/SB/05 (06-03)  
Approved for use through 07/31/2003. OMB 0651-0032U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL		Attorney Docket No.	PC19103B
		First Inventor	MICHAEL COLLINS
		Title	BENZOFUSED HETEROZRYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE
(Only for new nonapplications under 37C.F.R. §1.53(b))		Express Mail Label No.	EL 969716585 US
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO:	Mail Stop Patent Applications Commissioner for Patents Box 1450 Alexandria, VA 22313-1450
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)	<b>ACCOMPANYING APPLICATION PARTS</b> 9. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input checked="" type="checkbox"/> Power of Attorney (when there is an assignee) 11. <input type="checkbox"/> English Translation Document (if applicable) 12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 13. <input checked="" type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. <input type="checkbox"/> Other:	
2. <input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27	8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)		
3. <input checked="" type="checkbox"/> Specification [Total Pages <u>193</u> ] (preferred arrangement set forth below) <ul style="list-style-type: none"><li>- Descriptive title of the Invention</li><li>- Cross References to Related Applications</li><li>- Statement Regarding Fed sponsored R&amp;D</li><li>- Reference to sequence listing, a table, or a computer program listing appendix</li><li>- Background of the Invention</li><li>- Brief Summary of the Invention</li><li>- Brief Description of the Drawings (if filed)</li><li>- Detailed Description</li><li>- Claim(s)</li><li>- Abstract of the Disclosure</li></ul>	a. <input type="checkbox"/> Computer Readable Copy (CRF) b. Specification Sequence Listing on: <ul style="list-style-type: none"><li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies)</li><li>ii. <input type="checkbox"/> Paper</li></ul> c. <input type="checkbox"/> Statement verifying identity of above copies		
4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total sheets _____]			
5. <input checked="" type="checkbox"/> Oath or Declaration [Total pages <u>12</u> ] <ul style="list-style-type: none"><li>a. <input type="checkbox"/> Newly executed (original or copy)</li><li>b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR §1.63(d)) (for continuation/divisional with Box 18 completed)<ul style="list-style-type: none"><li>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</li></ul></li></ul>			
6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76			
18. If a <b>CONTINUING APPLICATION</b> , check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76. <input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>10/ 460,010</u> Prior application information: Examiner <u>Charanjit Aulakh</u> Group/Art Unit: <u>1625</u> For CONTINUATION OR DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The Incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts			
19. <b>CORRESPONDENCE ADDRESS</b> <input checked="" type="checkbox"/> Customer Number <u>28940</u> or <input type="checkbox"/> Correspondence address below			
Name _____ Address _____ City _____ State _____ Zip Code _____ Country _____ Telephone _____ Fax _____			
NAME (Print/type) Stephen D. Prodruk Registration No. (Attorney/Agent) 43,020 Signature <u>[Signature]</u> Date <u>02/09/04</u>			

17548 U.S. PTO  
10/796226

030904

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**FEE TRANSMITTAL  
for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small status. See 37 CFR 1.27**Total Amount of Payment** \$1,536.00**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit  
Account  
Number  
Deposit  
Account  
Name

500329

Agouron Pharmaceuticals, Inc.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE****Large Entity Small Entity**

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	770
1002	340	2002	170	Design filing fee	
1003	530	2203	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	filing fee	

Subtotal (1)s

\$ 770

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

	Extra Claims	Fee from below	Fee Paid
Total Claims	53	- 20** = 33	x 18.00 = 594.00
Independent Claims	5	- 3 = 2	x 86.00 = 172.00
Multiple Dependent			

**Large Entity Small Entity**

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	**Reissue independent claims over original patent
1205	18	2205	9	**Reissue independent claims over original patent

(\$) 1536.00

\*\*or number previously paid, if greater; For Reissues, see above

**Complete if Known**

Application Number	TBA
Filing Date	Herewith
First Named Inventor	MICHAEL COLLINS
Examiner Name	TBA
Art Unit	TBA
Attorney Docket No.	PC19103B

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**  
Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late fee or oath	
1052	50	2052	25	Surcharge-late filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for Ex Parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	


Other Fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

Subtotal (3)

(\$) -0-

**SUBMITTED BY**

Name (Printed/Type)	Stephen D. Prodnuk	Registration No.	43,020	Telephone	858-622-3087
Signature		(Attorney Agent)			


Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in completing the form, call 1-800-pto-9199 and select option 2.

PC19103B  
Divisional Application

Certificate of Mailing (37 C.F.R. §1.10):  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail (WL 969716585) in an envelope addressed  
to: Mail Stop: Patent Applications, Commissioner for  
Patents, PO Box 1450, Alexandria, VA 22313-1450  
on this 9th day of March 2004.

s/   
Julie Agozino

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
COLLINS, ET AL

Serial No.: To be assigned  
(DIV of 10/460,010)

Filed: Concurrently herewith

For: BENZOFUSED HETEROARYL AMIDE  
DERIVATIVES OF THIENOPYRIDINES  
USEFUL AS THERAPEUTIC AGENTS,  
PHARMACEUTICAL COMPOSITIONS  
INCLUDING THE SAME, AND METHODS  
FOR THEIR USE

Group Art Unit: 1625

Examiner: Charanjit Aulakh

Attorney Docket No. PC19103B

Mail Stop: Patent Applications  
Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

- |   |                    |
|---|--------------------|
| 1. Utility Patent Application Transmittal | 1 page;            |
| 2. Preliminary Amendment                  | 12 pages;          |
| 3. Declaration                            | 3 pages;           |
| 4. Power of Attorney                      | 9 pages;           |
| 5. Recordation Cover Sheet                | 2 pages;           |
| 6. Assignment                             | 5 pages;           |
| 7. Application Data Sheet                 | 4 pages;           |
| 8. Specification                          | 193 pages;         |
| 9. Fee Transmittal                        | 1 page + duplicate |
| 10. Information Disclosure Statement      | 2 pages;           |
| 11. Form (PTO.SB/08A)                     | 5 pages;           |
| 12. Return Postcard                       | 1 page; and        |
| 13. Total Fee Due \$1,536.00              | Deposit Account.   |

Respectfully submitted,



Stephen D. Prodnuk  
Attorney For Applicants  
Registration No. 43,020

Date: March 9, 2004

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3087  
Fax: (858) 678-8233